Our Conference on Precision Medicine is coming up and you are kindly invited to book the date in your calendar:
Precision Medicine: From Breakthroughs to Patient Benefit and Advancement in Direct to Consumer Testing
Wednesday, 29 September 2021
11:30 – 17:50 CEST (online event)
Organised by NM Genomix
Participation in the event is free of charge, but registration is required
Not long ago, personalised medicine was a topic from the future. This is not the case anymore. Personalised medicine is the new reality in healthcare. In this conference flow, we look at the advances, practices and challenges that are posed to different stakeholders in personalised medicines around the globe. We will cover the fields of psychiatry, neurology, prenatal and neonatal diagnostics, the microbiome and nutrigenetics, and genetic testing for better lifestyle choices.
Psychiatry: Pharmacogenetics and Personalised Practices
Neurology: Precision Medicine and Management
Prenatal and Neonatal Diagnostics
The Microbiome and Nutrigenetics
Genetic Testing for Better Lifestyle
All times are in Central European Summer Time (CEST) / UTC+2
Moderators and Speakers
Alekhya Narravula, MSc, MS, CGC
Daniel Dowd, PharmD, RPh
Dianalee McKnight, PhD, FACMG
Dimitrina Konstantinova-Kanazireva, Dr.
Hristo Ivanov, Dr.
Milena Georgieva, Assoc. Prof.
Nevyana Ivanova, PhD
Nikolaus Gasche, Dr.
Olga Antonova, MD, PhD
Prof. Dr. Dobrin Svinarov, MD. PhD, Dr. Med Sc
Sarper Diler, Prof. Dr A. (M.D., PhD, CHTC, Hom)
Seema Patel, PharmD, BCPP
Victoria Sarafian, Prof. Dr. MD, PhD, DMSc
About NM Genomix
NM Genomix’s main aim is to introduce and implement the latest medical technologies available in interest of patients. By providing innovative medical products, diagnostic solutions and services of the highest quality, we strive to provide our customers with access to the highest standards in healthcare. The company’s activity is focused on the integration of globally established genetic analyses and diagnostics to the Bulgarian market. The fields of interest are diverse, but still each of them with extreme importance for us and our clients – prenatal (NIPT) and neonatal tests, diagnostics for prediction, evaluation and monitoring the effectiveness of therapy for cancer patients, according to the individual profile of the disease, as well as pharmacogenetic tests that allow clinicians to choose the most appropriate therapy and optimize treatment regimens for patients with psychiatric disorders. Our newest additions to the portfolio of tests – Microbiome Passport and LifeGenomix, that analyse gut microbiome of each individual (Microbiome Passport) and different genes related to lifestyle – nutrition, fitness and skin (LifeGenomix) allow the consumer to achieve a better way of living suited to their individual profile and genetic characteristics.
Feel free to get in touch